ImmunoFree

ImmunoFree is a biotechnology company founded in 2023 with the mission to eliminate the need for lifelong immunosuppressive medications in organ transplant recipients. The company acquired the tolerance business of Talaris Therapeutics, including its lead cell therapy candidate FCR001, which is designed to induce immune tolerance through persistent mixed chimerism. ImmunoFree is currently focused on advancing FCR001 for kidney transplant recipients, leveraging the National Kidney Registry's matching capabilities to improve patient outcomes. By establishing a stable combination of donor and recipient cells, the therapy aims to prevent organ rejection while allowing patients to live free from the side effects of chronic immunosuppression. The company is supported by the National Kidney Foundation Innovation Fund and led by a team of prominent transplant surgeons and researchers.